According to basic survey results, the existing main problems for coagulation testing include nonunified standardization, insufficient academic knowledge of blood coagulation, less equipment, few testing items, insufficient sample size, insufficient clinical communication, etc.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The US Food and Drug Administration (FDA) has set an “aggressive” timeline to implement generative artificial intelligence (genAI) across the agency by 30 June 2025.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025.

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2025.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025.

Siemens Healthineers AG today announces its results for the second quarter of fiscal year 2025 ended March 31, 2025.

As of April 30, 2025, there are 82 publicly listed companies in China engaged in the in vitro diagnostics (IVD) industry. Among them, 61 companies focus primarily on IVD, while 21 have IVD as part of their broader business portfolios.

Diasorin said Tuesday that the firm's first quarter revenues jumped 8 percent year over year with growth across the company's immunodiagnostics, molecular diagnostics, and licensed technologies businesses.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025.

In 2024, China’s IVD market size is expected to be less than RMB 120 billion, remaining flat compared to 2023. Domestic brands account for approximately 50% of the market.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire Capsulomics, Inc., d/b/a Previse. Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases, including esophageal cancer. The terms of the agreement are undisclosed.